Universität zu Köln

Pinggera, Alexandra, Mackenroth, Luisa, Rump, Andreas, Schallner, Jens, Beleggia, Filippo ORCID: 0000-0003-0234-7094, Wollnik, Bernd and Striessnig, Joerg ORCID: 0000-0002-9406-7120 (2017). New gain-of-function mutation shows CACNA1D as recurrently mutated gene in autism spectrum disorders and epilepsy. Hum. Mol. Genet., 26 (15). S. 2923 - 2933. OXFORD: OXFORD UNIV PRESS. ISSN 1460-2083

Full text not available from this repository.

Abstract

CACNA1D encodes the pore-forming alpha 1-subunit of Cav1.3, an L-type voltage-gated Ca2+-channel. Despite the recent discovery of two de novo missense gain-of-function mutations in Cav1.3 in two individuals with autism spectrum disorder (ASD) and intellectual disability CACNA1D has not been considered a prominent ASD-risk gene in large scale genetic analyses, since such studies primarily focus on likely-disruptive genetic variants. Here we report the discovery and characterization of a third de novo missense mutation in CACNA1D (V401L) in a patient with ASD and epilepsy. For the functional characterization we introduced mutation V401L into two major C-terminal long and short Cav1.3 splice variants, expressed wild-type or mutant channel complexes in tsA-201 cells and performed whole-cell patch-clamp recordings. Mutation V401L, localized within the channel's activation gate, significantly enhanced current densities, shifted voltage dependence of activation and inactivation to more negative voltages and reduced channel inactivation in both Cav1.3 splice variants. Altogether, these gating changes are expected to result in enhanced Ca2+-influx through the channel, thus representing a strong gain-of-function phenotype. Additionally, we also found that mutant channels retained full sensitivity towards the clinically available Ca2+-channel blocker isradipine. Our findings strengthen the evidence for CACNA1D as a novel candidate autism risk gene and encourage experimental therapy with available channel-blockers for this mutation. The additional presence of seizures and neurological abnormalities in our patient define a novel phenotype partially overlapping with symptoms in two individuals with PASNA (congenital primary aldosteronism, seizures and neurological abnormalities) caused by similar Cav1.3 gain-of-function mutations.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Pinggera, Alexandra UNSPECIFIED UNSPECIFIED UNSPECIFIED Mackenroth, Luisa UNSPECIFIED UNSPECIFIED UNSPECIFIED Rump, Andreas UNSPECIFIED UNSPECIFIED UNSPECIFIED Schallner, Jens UNSPECIFIED UNSPECIFIED UNSPECIFIED Beleggia, Filippo UNSPECIFIED orcid.org/0000-0003-0234-7094 UNSPECIFIED Wollnik, Bernd UNSPECIFIED UNSPECIFIED UNSPECIFIED Striessnig, Joerg UNSPECIFIED orcid.org/0000-0002-9406-7120 UNSPECIFIED
URN:	urn:nbn:de:hbz:38-224074
DOI:	10.1093/hmg/ddx175
Journal or Publication Title:	Hum. Mol. Genet.
Volume:	26
Number:	15
Page Range:	S. 2923 - 2933
Date:	2017
Publisher:	OXFORD UNIV PRESS
Place of Publication:	OXFORD
ISSN:	1460-2083
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language DE-NOVO MUTATIONS; CA2+ CHANNELS; CA(V)1.3 CHANNELS; CALCIUM-CHANNELS; BASOLATERAL AMYGDALA; CHROMAFFIN CELLS; DOMAIN; INACTIVATION; MODULATION; MECHANISMS Multiple languages Biochemistry & Molecular Biology; Genetics & Heredity Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/22407